Our observations align with the STEP-HFpEF and SELECT trials, which demonstrated CV benefit of semaglutide in individuals with overweight or obesity.9,10 The CV benefits of GLP-1 RAs in patients with overweight may be attributed to their multiple mechanisms of action on insulin sensitivity and inflammation. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.